Inclusion Criteria:

          -  Participants must be newly diagnosed, treatment-naive with histologically confirmed
             stage IIIC unresectable melanoma or stage IV melanoma

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Available archival formalin-fixed paraffin-embedded (FFPE) from a prior biopsy or,
             participant must be willing to have a tissue biopsy taken at a clinic visit prior to
             start of study treatment

          -  Have measurable disease per irRECIST v1.1

          -  Ability to swallow and retain oral medication

          -  Absolute neutrophil count (ANC) >= 1500/uL

          -  Hemoglobin (Hb) >= 9 g/dL

          -  Platelet count >= 100, 000/uL

          -  Total bilirubin =< 1.5 x ULN (upper limit of normal) - unless patient has Gilbert's
             syndrome

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN

          -  If the patient has liver metastasis AST and ALT less than or greater to 5x ULN

          -  Serum creatinine < 2 x ULN

          -  Participants of child-bearing potential must have a negative pregnancy test at study
             entry and then agree to use adequate contraceptive methods (e.g., hormonal or barrier
             method of birth control; abstinence) prior to study entry; should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Participants who have received previous immunotherapy for any cancer (excluding
             melanoma) including PD-1/PD-L1 inhibitors but not interferons and CTLA-4 inhibitors

          -  Participants with chronic autoimmune diseases

          -  Participants with symptomatic known brain metastases < 4 weeks from radiation
             treatment should be excluded from this clinical trial

          -  Other invasive cancers diagnosed < 3 years back that required systemic treatment. If
             diagnosed with other invasive cancer >=3 years, should have complete recovery from all
             systemic toxicity except neuropathy and alopecia

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant or nursing female participants, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug

          -  Other active non-melanoma metastatic cancers

          -  Contraindications to the use of beta-blockers, like, uncontrolled depression, unstable
             angina pectoris, uncontrolled heart failure (grade III or IV), hypotension (systolic
             blood pressure < 100 mmHg), severe asthma or chronic obstructive pulmonary disease
             (COPD), uncontrolled type I or type II diabetes mellitus (glycosylated hemoglobin
             [HbA1C] > 8.5 or fasting plasma glucose > 160 mg/dl at screening), symptomatic
             peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current
             use or past use in the last two years of beta-blockers or non-dihydropyridine calcium
             channel blockers

          -  Patient is currently receiving or has received systemic corticosteroids (=< 2 weeks
             prior to starting study drug, or who have not fully recovered from side effects of
             such treatment)

          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form
             of immunosuppressive therapy within 14 days prior to the first dose of the study drug

          -  Has received a live vaccine or live-attenuated vaccine within 30 days prior to the
             first dose of trial treatment and while participating in the trial. Examples of live
             vaccines include, but are not limited to, the following: measles, mumps, rubella,
             varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Administration of
             killed vaccines is allowed.